查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1580008

困難梭狀芽孢桿菌治療市場：依治療類型、給藥途徑、患者年齡層和最終用戶 - 2025-2030 年全球預測

Clostridium Difficile Treatment Market by Treatment Type (Antibiotics Treatment, Non-Antibiotic Treatment), Route of Administration (Oral, Parenteral), Patient Age Group, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，困難梭狀芽孢桿菌治療市值為88.2億美元，預計2024年將達到94.1億美元，複合年成長率為6.89%，預計到2030年將達到140.7億美元。

困難梭狀芽孢桿菌治療市場包括一系列診斷、治療和預防解決方案，旨在對抗困難梭狀芽孢桿菌細菌引起的感染疾病，這種細菌通常會導致嚴重腹瀉和結腸炎。高感染復發率、抗生素抗藥性以及與艱難梭菌感染疾病(CDI) 相關的顯著發病率推動了對有效治療的需求。應用領域主要涵蓋醫療保健領域，包括醫院、專科診所和長期照護機構。最終用途集中於醫療保健提供者、患者和看護者，尋求減少感染疾病的發生率並改善患者的治療結果。

主要市場統計
基準年[2023] 88.2億美元
預測年份 [2024] 94.1億美元
預測年份 [2030] 140.7億美元
複合年成長率（%） 6.89%

關鍵的成長要素包括 CDI 發病率上升、人口老化、住院率上升以及對抗生素相關腹瀉的認知提高。此外，微生物組研究和糞便微生物群移植（FMT）的進步正在帶來創新的治療方法。市場看到了開發窄頻譜抗生素、有效疫苗和旨在恢復健康腸道菌叢的新型益生菌的潛在機會。然而，先進治療方法的高成本、嚴格的監管要求以及與微生物治療相關的複雜性等限制構成了重大挑戰。抗生素抗藥性的風險和目前治療方法的有限有效性進一步加劇了市場的不可預測性。

需要創新的領域包括研究侵入性較小的微生物組修復技術、開發副作用較少的替代療法，以及早期檢測 CDI 發病的有效診斷工具。此外，探索合成生物學以生產靶向噬菌體和工程益生菌作為潛在的治療方法也具有潛力。由於正在進行的臨床研究以及生物技術公司和學術機構之間不斷加強的合作，市場的性質仍然高度活躍。為了抓住新的商機，相關人員應投資強大的研發開發平臺，並建立策略夥伴關係關係，以實現創新的快速開發和商業化。保持監管合規性並倡導更透明的報銷政策也將有助於緩解市場限制。

市場動態：揭示快速發展的困難梭狀芽孢桿菌治療市場的關鍵市場洞察

供需的動態交互作用正在改變困難梭狀芽孢桿菌藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 困難梭狀芽孢桿菌傳染病盛行率上升
    • 關注預防策略和益生菌
    • 提高醫療保健意識和治療困難梭狀芽孢桿菌傳染病的舉措
  • 市場限制因素
    • 抗生素抗藥性和復發率
  • 市場機會
    • 開發標靶治療
    • 診斷工具和技術的進步
  • 市場挑戰
    • 準確診斷的複雜性和法規遵循的限制

波特五力戰略工具駕馭困難梭狀芽孢桿菌藥物市場

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對困難梭狀芽孢桿菌治療市場的影響

外部宏觀環境因素在塑造困難梭狀芽孢桿菌治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解困難梭狀芽孢桿菌治療藥物市場的競爭狀況

對困難梭狀芽孢桿菌治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位困難梭狀芽孢桿菌治療市場供應商的績效評估

FPNV 定位矩陣是評估困難梭狀芽孢桿菌治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪困難梭狀芽孢桿菌治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對困難梭狀芽孢桿菌治療市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 困難梭狀芽孢桿菌傳染病盛行率上升
      • 關注預防策略和益生菌
      • 提高醫療保健意識和參與治療困難梭狀芽孢桿菌傳染病
    • 抑制因素
      • 抗生素抗藥性和復發率
    • 機會
      • 開發標靶治療和先進治療
      • 診斷工具和技術的進步
    • 任務
      • 準確診斷的複雜性和法規遵循的限制
  • 市場區隔分析
    • 治療類型：為了降低復發率並儘量減少對腸道菌叢的影響，對非達黴素的需求量很大。
    • 最終使用者：提高醫院和診所困難梭狀芽孢桿菌治療的可用性
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章困難梭狀芽孢桿菌治療藥物市場（依治療類型）

  • 抗生素治療
    • 非達黴素
    • 甲硝唑
    • 萬古黴素
  • 無需抗生素治療
    • 糞便微生物移植
    • 益生菌

第7章困難梭狀芽孢桿菌治療市場：依給藥途徑

  • 口服
  • 胃腸外的

第 8 章依病患年齡層別困難梭狀芽孢桿菌治療市場

  • 成人
  • 老年病
  • 小兒科

第 9 章困難梭狀芽孢桿菌治療市場：依最終用戶

  • 家庭保健
  • 醫院/診所

第10章美洲困難梭狀芽孢桿菌治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區困難梭狀芽孢桿菌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲困難梭狀芽孢桿菌治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Vedanta Biosciences 正在三期試驗中推進 VE303，以對抗復發性困難梭狀芽孢桿菌傳染病，著眼於市場核准和策略投資。
    • 在 FDA核准完成治療困難梭狀芽孢桿菌的 2 期臨床試驗後，Acurx Pharmaceuticals 正在將 ivezapolstat 推進到 3 期臨床試驗。
  • 戰略分析和建議

公司名單

  • Acurx Pharmaceuticals, Inc.
  • Aridis Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • GlaxoSmithKlinePLC
  • Immuron Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Pfizer, Inc.
  • Rebiotix Inc
  • Roche Holding AG
  • Seres Therapeutics, Inc.
  • Summit Therapeutics, Inc.
  • Synthetic Biologics, Inc.
  • Thermo Fisher Scientific, Inc.
  • Trinity Biotech PLC
  • Vedanta Biosciences, Inc.
Product Code: MRR-AA6346B014A7

The Clostridium Difficile Treatment Market was valued at USD 8.82 billion in 2023, expected to reach USD 9.41 billion in 2024, and is projected to grow at a CAGR of 6.89%, to USD 14.07 billion by 2030.

The Clostridium Difficile Treatment market encompasses a range of diagnostic, therapeutic, and preventive solutions aimed at addressing infections caused by the Clostridium difficile bacterium, which often leads to severe diarrhea and colitis. The necessity for effective treatments is driven by high infection recurrence rates, antibiotic resistance, and the significant morbidity associated with C. difficile infections (CDIs). Application areas primarily span across the healthcare sector, including hospitals, specialty clinics, and long-term care facilities. End-use is concentrated among healthcare providers, patients, and caregivers, seeking to reduce incidences and improve patient outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 8.82 billion
Estimated Year [2024] USD 9.41 billion
Forecast Year [2030] USD 14.07 billion
CAGR (%) 6.89%

Key growth factors include rising incidences of CDIs, an aging population, increased hospitalization rates, and greater awareness of antibiotic-associated diarrhea. Additionally, advancements in microbiome research and fecal microbiota transplantation (FMT) have spearheaded innovative treatment approaches. The market is witnessing potential opportunities in the development of narrow-spectrum antibiotics, effective vaccines, and novel probiotics aimed at restoring healthy gut flora. However, limitations such as the high cost of advanced therapies, stringent regulatory requirements, and the complexities associated with microbiome-based treatments present significant challenges. The risks of antibiotic resistance and limited efficacy of current treatments further underscore market unpredictability.

Areas ripe for innovation include research into less invasive microbiome restoration techniques, development of alternative therapies with fewer side effects, and more efficient diagnostic tools for early detection of CDI onset. Additionally, there lies potential in exploring synthetic biology for producing targeted bacteriophages or engineered probiotics as promising interventions. The market's nature remains highly dynamic due to ongoing clinical studies and increasing collaboration between biotechnology firms and academic institutions. To seize emerging opportunities, stakeholders should invest in robust R&D pipelines and foster strategic partnerships for faster development and commercialization of their innovations. Maintaining regulatory compliance and advocating for more transparent reimbursement policies can also help mitigate market limitations.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Clostridium Difficile Treatment Market

The Clostridium Difficile Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of Clostridium difficile infection
    • Focus on preventive strategies and probiotics
    • Increased healthcare awareness and initiatives to treat clostridium difficile infection
  • Market Restraints
    • Antibiotic resistance and recurrence rates
  • Market Opportunities
    • Development of targeted and advanced therapies
    • Advancements in diagnostic tools and techniques
  • Market Challenges
    • Complexity of accurate diagnosis and limitations in regulatory compliance

Porter's Five Forces: A Strategic Tool for Navigating the Clostridium Difficile Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Clostridium Difficile Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Clostridium Difficile Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Clostridium Difficile Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Clostridium Difficile Treatment Market

A detailed market share analysis in the Clostridium Difficile Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Clostridium Difficile Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Clostridium Difficile Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Clostridium Difficile Treatment Market

A strategic analysis of the Clostridium Difficile Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Clostridium Difficile Treatment Market, highlighting leading vendors and their innovative profiles. These include Acurx Pharmaceuticals, Inc., Aridis Pharmaceuticals, Inc., Astellas Pharma Inc., AstraZeneca PLC, GlaxoSmithKlinePLC, Immuron Limited, Merck & Co., Inc., Mylan N.V., Pfizer, Inc., Rebiotix Inc, Roche Holding AG, Seres Therapeutics, Inc., Summit Therapeutics, Inc., Synthetic Biologics, Inc., Thermo Fisher Scientific, Inc., Trinity Biotech PLC, and Vedanta Biosciences, Inc..

Market Segmentation & Coverage

This research report categorizes the Clostridium Difficile Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Antibiotics Treatment and Non-Antibiotic Treatment. The Antibiotics Treatment is further studied across Fidaxomicin, Metronidazole, and Vancomycin. The Non-Antibiotic Treatment is further studied across Fecal Microbiota Transplantation and Probiotics.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Patient Age Group, market is studied across Adults, Geriatric, and Pediatric.
  • Based on End-User, market is studied across Home Healthcare and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of Clostridium difficile infection
      • 5.1.1.2. Focus on preventive strategies and probiotics
      • 5.1.1.3. Increased healthcare awareness and initiatives to treat clostridium difficile infection
    • 5.1.2. Restraints
      • 5.1.2.1. Antibiotic resistance and recurrence rates
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of targeted and advanced therapies
      • 5.1.3.2. Advancements in diagnostic tools and techniques
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of accurate diagnosis and limitations in regulatory compliance
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Growing demand for Fidaxomicin to ensure low recurrence rates and minimal disruption to the gut microbiome
    • 5.2.2. End User: Increasing availability of clostridium difficile treatment across hospitals and clinics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Clostridium Difficile Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Antibiotics Treatment
    • 6.2.1. Fidaxomicin
    • 6.2.2. Metronidazole
    • 6.2.3. Vancomycin
  • 6.3. Non-Antibiotic Treatment
    • 6.3.1. Fecal Microbiota Transplantation
    • 6.3.2. Probiotics

7. Clostridium Difficile Treatment Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral

8. Clostridium Difficile Treatment Market, by Patient Age Group

  • 8.1. Introduction
  • 8.2. Adults
  • 8.3. Geriatric
  • 8.4. Pediatric

9. Clostridium Difficile Treatment Market, by End-User

  • 9.1. Introduction
  • 9.2. Home Healthcare
  • 9.3. Hospitals & Clinics

10. Americas Clostridium Difficile Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Clostridium Difficile Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Clostridium Difficile Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Vedanta Biosciences advances VE303 in phase III trial to combat recurrent c. difficile infections, eyes market approval, and strategic investments
    • 13.3.2. Acurx Pharmaceuticals advances Ibezapolstat to phase 3 clinical trials following FDA end-of-phase 2 approval for clostridium difficile treatment
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Acurx Pharmaceuticals, Inc.
  • 2. Aridis Pharmaceuticals, Inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. GlaxoSmithKlinePLC
  • 6. Immuron Limited
  • 7. Merck & Co., Inc.
  • 8. Mylan N.V.
  • 9. Pfizer, Inc.
  • 10. Rebiotix Inc
  • 11. Roche Holding AG
  • 12. Seres Therapeutics, Inc.
  • 13. Summit Therapeutics, Inc.
  • 14. Synthetic Biologics, Inc.
  • 15. Thermo Fisher Scientific, Inc.
  • 16. Trinity Biotech PLC
  • 17. Vedanta Biosciences, Inc.

LIST OF FIGURES

  • FIGURE 1. CLOSTRIDIUM DIFFICILE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CLOSTRIDIUM DIFFICILE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CLOSTRIDIUM DIFFICILE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CLOSTRIDIUM DIFFICILE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CLOSTRIDIUM DIFFICILE TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY FIDAXOMICIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY METRONIDAZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY FECAL MICROBIOTA TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. SINGAPORE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. SINGAPORE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. TAIWAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. TAIWAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. VIETNAM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. VIETNAM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 151. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 247. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 253. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 259. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 265. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 277. CLOSTRIDIUM DIFFICILE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 278. CLOSTRIDIUM DIFFICILE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023